X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

ALEMBIC LIMITED  (ALMC)


Here is the latest financial fact sheet of ALEMBIC LTD. For more details, see the ALEMBIC LTD quarterly results and ALEMBIC LTD share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
alembic ltd - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 48.2       No. of shares m 553.80
    Mkt Cap Rs m 26,693       % ch % -2.9
    Vol '000 573.3       % ch week % 10.0
    P/E X 114.8       % ch 1-mth % 34.1
    P/CF X 83.8       % ch 12-mth % 22.5
    EPS (TTM) Rs 0.4       52 week H/L Rs 51.7/32.4
(As on Apr 26, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-10
12
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs5677402018 
Low Rs314314147 
Sales per share (Unadj.) Rs76.515.19.013.45.8 
Earnings per share (Unadj.) Rs1.5-1.0-0.90.91.1 
Diluted earnings per shareRs0.4-0.2-0.20.20.5 
Cash flow per share (Unadj.) Rs4.8-0.2-0.11.61.2 
Dividends per share (Unadj.) Rs0.50000.200.15 
Adj. dividends per shareRs0.120.000.000.050.07 
Dividend yield (eoy) %1.1001.21.2 
Book value per share (Unadj.) Rs23.615.714.815.48.6 
Adj. book value per shareRs5.73.83.63.74.2 
Shares outstanding (eoy) m133.52133.52133.52133.52267.03 
Bonus/Rights/Conversions  BB---B1:1 
Price / Sales ratio x0.64.03.01.32.1 
Avg P/E ratio x28.1-62.1-29.519.811.2 
P/CF ratio (eoy) x9.1-283.1-283.910.610.4 
Price / Book Value ratio x1.83.81.81.11.4 
Dividend payout %32.30023.213.6 
Avg Mkt Cap Rs m5,8088,0113,6052,2703,298 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,699297255245273 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m10,2152,0191,2081,7921,536 
Other income Rs m433665103158 
Total revenues Rs m10,2582,0551,2721,8951,694 
Gross profit Rs m92330-15157223 
Depreciation Rs m4301011099823 
Interest Rs m30134525123 
Profit before tax Rs m236-68-111110335 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0-42-2500 
Tax Rs m2918-14-539 
Profit after tax Rs m207-129-122115295 
Gross profit margin %9.01.5-1.28.714.5 
Effective tax rate %12.2-26.912.7-4.411.8 
Net profit margin %2.0-6.4-10.16.419.2 
  BALANCE SHEET DATA
Current assets Rs m5,5861,1941,7001,2901,543 
Current liabilities Rs m5,7011,2891,6311,070907 
Net working cap to sales %-1.1-4.75.712.341.4 
Current ratio x1.00.91.01.21.7 
Inventory Days Days88113285198248 
Debtors Days Days6785483766 
Net fixed assets Rs m3,9712,0221,9541,8841,800 
Share capital Rs m267267267267534 
"Free" reserves Rs m2,730620498892874 
Net worth Rs m3,1572,0941,9722,0582,307 
Long term debt Rs m64600302331 
Total assets Rs m9,6423,3983,9153,4403,562 
Interest coverage x1.8-1.0-1.13.115.4 
Debt to equity ratio x0.2000.10.1 
Sales to assets ratio x1.10.60.30.50.4 
Return on assets %5.3-2.8-1.84.88.9 
Return on equity %6.5-6.2-6.25.612.8 
Return on capital %14.1-3.7-4.36.813.6 
Exports to sales %30.610.57.14.47.7 
Imports to sales %10.36.35.40.93.4 
Exports (fob) Rs m3,1262128679118 
Imports (cif) Rs m1,055127661752 
Fx inflow Rs m3,1262128679118 
Fx outflow Rs m1,311136703863 
Net fx Rs m1,81476164155 
  CASH FLOW
From Operations Rs m 1,274 152 -591 803 -102 
From Investments Rs m -235 -203 -54 121 178 
From Financial Activity Rs m -1,182 66 646 -943 -79 
Net Cashflow Rs m -142 14 1 -19 -3 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for alembic limited

 Share Holding
Indian Promoters : 64.0%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 0.2%
FIIs : 9.7%
ADR/GDR : 0.0%
Free float : 26.1%
Shareholders : 54,701
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Alembic Road, Vadodara - 390 003
    E-MAIL: alembic.investors@alembic.co.in     WEB: www.alembiclimited.com
    TELEPHONE: (0265) 228 0550     FAX: (0265) 228 2506
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, B-102-103, Shangrila Complex, 1st Flr., Akota, Vadodara-20
    AUDITOR: K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Chirag K. Shukla YEAR OF INC: 1907 BSE CODE: 506235 FV (Rs): 2 DIV YIELD (%): 0.2

More pharmaceuticals Company Fact Sheets:   CIPLAASTRAZENECA PHARMATTK HEALTHCAREFDC LTD.AMAR REMEDIES


Today's Market

Sensex & Nifty Close at All-Time Highs; M&M Tops the Gainers(Closing)

Share markets in India finished on a strong footing on positive global cues, strengthening of rupee, healthy corporate earnings and FII inflows into the market.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC LTD

ALEMBIC LTD - ADCOCK INGRAM COMPARISON

Compare Company With Charts

COMPARE ALEMBIC LTD WITH

MARKET STATS